



University of HUDDERSFIELD

University of Huddersfield Repository

Tiede, C, Tang, AA, Deacon, Sarah E., Mandal, U, Nettleship, JE, Owen, RL, George, SE, Harrison, DJ, Owens, RJ, Tomlinson, DC and McPherson, MJ

Adhiron: a stable and versatile peptide display scaffold for molecular recognition applications

Original Citation

Tiede, C, Tang, AA, Deacon, Sarah E., Mandal, U, Nettleship, JE, Owen, RL, George, SE, Harrison, DJ, Owens, RJ, Tomlinson, DC and McPherson, MJ (2014) Adhiron: a stable and versatile peptide display scaffold for molecular recognition applications. *Protein Engineering Design and Selection*, 27 (5). pp. 145-155. ISSN 1741-0126,

This version is available at <http://eprints.hud.ac.uk/29681/>

The University Repository is a digital collection of the research output of the University, available on Open Access. Copyright and Moral Rights for the items on this site are retained by the individual author and/or other copyright owners. Users may access full items free of charge; copies of full text items generally can be reproduced, displayed or performed and given to third parties in any format or medium for personal research or study, educational or not-for-profit purposes without prior permission or charge, provided:

- The authors, title and full bibliographic details is credited in any copy;
- A hyperlink and/or URL is included for the original metadata page; and
- The content is not changed in any way.

For more information, including our policy and submission procedure, please contact the Repository Team at: E.mailbox@hud.ac.uk.

<http://eprints.hud.ac.uk/>

Adhiron: a stable and versatile peptide display scaffold for molecular recognition applications

Christian Tiede^{1,2}, Anna A. S. Tang^{1,2}, Sarah E. Deacon^{2,3},
Upasana Mandal^{1,2}, Joanne E. Nettleship^{4,5},
Robin L. Owen⁶, Suja E. George^{2,3}, David J. Harrison²,
Raymond J. Owens^{4,5}, Darren C. Tomlinson^{1,2,3,7} and
Michael J. McPherson^{1,2,3,7}

¹Biomedical Health Research Centre, BioScreening Technology Group, University of Leeds, Leeds LS2 9JT, UK, ²School of Molecular and Cellular Biology, University of Leeds, Leeds LS2 9JT, UK, ³Astbury Centre for Structural Molecular Biology, Faculty of Biological Sciences, University of Leeds, Leeds LS2 9JT, UK, ⁴The Oxford Protein Production Facility UK, Research Complex at Harwell, Rutherford Appleton Laboratory, Harwell Science and Innovation Campus, Didcot, Oxfordshire OX11 0FA, UK, ⁵Division of Structural Biology, University of Oxford, Wellcome Trust Centre for Human Genetics, Roosevelt Drive, Oxford OX3 7BN, UK and ⁶Diamond Light Source, Harwell Science and Innovation Campus, Didcot, Oxfordshire OX11 0DE, UK

⁷To whom correspondence should be addressed.
E-mail: m.j.mcpherson@leeds.ac.uk (M.J.M.); d.c.tomlinson@leeds.ac.uk (D.C.T.)

Received November 18, 2013; revised February 20, 2014;
accepted February 25, 2014

Edited by Dario Neri

We have designed a novel non-antibody scaffold protein, termed Adhiron, based on a phycocystatin consensus sequence. The Adhiron scaffold shows high thermal stability (T_m ca. 101°C), and is expressed well in *Escherichia coli*. We have determined the X-ray crystal structure of the Adhiron scaffold to 1.75 Å resolution revealing a compact cystatin-like fold. We have constructed a phage-display library in this scaffold by insertion of two variable peptide regions. The library is of high quality and complexity comprising 1.3×10^{10} clones. To demonstrate library efficacy, we screened against the yeast Small Ubiquitin-like Modifier (SUMO). In selected clones, variable region 1 often contained sequences homologous to the known SUMO interactive motif (V/I-X-V/I-V/I). Four Adhiron scaffolds were further characterised and displayed low nanomolar affinities and high specificity for yeast SUMO with essentially no cross-reactivity to human SUMO protein isoforms. We have identified binders against >100 target molecules to date including as examples, a fibroblast growth factor (FGF1), platelet endothelial cell adhesion molecule (PECAM-1; CD31), the SH2 domain Grb2 and a 12-aa peptide. Adhiron scaffolds are highly stable and well expressed allowing highly specific binding reagents to be selected for use in molecular recognition applications.

Keywords: consensus protein/high specificity binding/
non-antibody-binding protein/protein–protein interaction/
SUMO

Introduction

Antibodies are the most commonly used binding proteins with >240 candidates in clinical development (Reichert, 2010) and remain extremely important in scientific research, diagnostics and therapy. Nevertheless, antibodies have a number of limitations; they are large multimeric proteins that require disulphide bonds and glycosylation for stability. They are usually difficult to express in bacterial systems and are often highly sensitive to elevated temperatures. Antibody production is generally expensive, relies upon the use of animals and mammalian cell culture, while for clinical applications they must be engineered as humanised versions. Protein engineering has been exploited to develop alternative non-antibody binding proteins which mimic the molecular recognition properties of antibodies but with some improved properties.

Some 50 novel non-antibody protein scaffolds have been designed to constrain and present variable peptide sequences for protein recognition (Skerra, 2007; Gebauer and Skerra, 2009). These include designed ankyrin repeat proteins (DARPin) (Binz *et al.*, 2003), Repebodies (Lee *et al.*, 2012), Anticalins (Schlehuber and Skerra, 2005), Fibronectins (Koide *et al.*, 1998), Affibodies (Nord *et al.*, 1995) and engineered Kunitz domains (Nixon and Wood, 2006). Artificial binding proteins are in general small (<200 aa), monomeric, stable and easy to express in *Escherichia coli*. Most do not contain cysteines enabling the introduction of a cysteine for site-specific coupling of biotin, fluorescent labels, or polyethylene glycol to enhance their utility or stability. These characteristics make artificial binding proteins powerful tools capable of replacing antibodies in a range of applications including research (Wojcik *et al.*, 2010), diagnostics (Theurillat *et al.*, 2010), *in vivo* drug discovery studies (Grebien *et al.*, 2011; Parizek *et al.*, 2012) and a novel class of therapeutics (recently reviewed (Gebauer and Skerra, 2009; Wurch *et al.*, 2012)) including multivalent and/or multi-specific protein therapeutics (Carter, 2011). A potential disadvantage of small artificial proteins for therapeutic purposes is a short circulatory half-life; however, this can be overcome by fusing them to larger proteins such as albumin or by using PEGylation or PASylation (XL-Protein GmbH) or XTEN (Schellenberger *et al.*, 2009) approaches.

An important consideration when designing artificial protein scaffolds is their thermostability. In general, there is a correlation between thermal stability and other aspects of protein stability, so a highly stable scaffold enables long-term storage at ambient temperature and also broadens utility in a range of processes including heat purification and options for the storage of reagents and administration of therapeutics. Insertion of peptide loops into a scaffold often leads to a decrease in protein stability so it is desirable to select a very stable scaffold for combinatorial library generation. One approach to generate





Fig. 1. Adhiron coding region and phagemid vector. (A) Codon optimized coding sequence and amino acid sequence of the Adhiron92 scaffold with secondary structure elements indicated. The residues that are replaced by the nine randomized amino acids (X) to form LOOP1 and LOOP2 in the Adhiron library are boxed. In place of the N-terminal residues AlaThrGly, the original consensus sequence contained the N-terminal sequence AlaAlaLeuLeuGlyGly. (B) pBSTG1 phagemid vector containing the coding region for Adhiron92 indicating relevant features of the construct.

25°C and 170 rpm. Phage were precipitated with 4% polyethylene glycol 8000, 0.3 M NaCl and resuspended in 1 ml of 10 mM Tris, pH 8.0, 1 mM EDTA (TE buffer). A 2 µl aliquot of phage suspension was used for the second round of selection using streptavidin magnetic beads (Invitrogen). Yeast SUMO labelled beads were washed and incubated with pre-panned phage for 1 h then washed five times using a

KingFisher robotic platform (ThermoFisher) and eluted and amplified as above. The final pan used neutravidin high binding capacity plates (Pierce), as previously described for panning round one, with phage eluted using 100 µl of 100 mM dithiothreitol. Phage were recovered from wells containing target protein and control wells to determine the level of amplification in target wells.

Phage ELISA

Individual ER2738 colonies were grown in 100 μ l of 2TY with 100 μ g/ml of carbenicillin in a 96-deep well plate at 37°C (900 rpm) for 6 h. A 25 μ l aliquot of the culture was added to 200 μ l of 2TY containing carbenicillin and grown at 37°C (900 rpm) for 1 h. Helper phage (10 μ l of 10^{11} /ml) were added, followed by kanamycin to 25 μ g/ml overnight and incubated at 25°C (450 rpm). Streptavidin-coated plates (Pierce) were blocked with 2 \times casein blocking buffer (Sigma) overnight at 37°C. The plates were incubated with biotinylated yeast SUMO or biotinylated linker for 1 h, and 45 μ l of growth medium containing the phage was added and incubated for 1 h. Following washing, phage were detected by a 1 : 1000 dilution of HRP-conjugated anti-phage antibody (Seramun) for 1 h, visualised with 3,3',5,5'-tetramethylbenzidine (TMB) (Seramun) and measured at 610 nm.

Adhiron protein production

The DNA coding sequences of Adhiron were amplified by PCR, restriction digested with NheI and PstI and cloned into pET11a containing the Adhiron scaffold similarly digested. Plasmid DNA was purified (Qiagen) from transformant colonies and sequenced to confirm the correct insert. Following transformation into BL21 (DE3) cells (*F⁻ ompT gal dcm lon hsdS_B(r_B⁻ m_B⁻) λ (DE3 [lacI lacUV5-T7 gene 1 ind1 sam7 nin5])*) 400 ml cultures in LB medium were induced with 0.1 mM IPTG. Cells were grown for 6 h, harvested and lysed with Bugbuster (Novagen). The clear supernatant was mixed with 500 μ l of Ni-NTA resin slurry (Qiagen) for 1 h, washed three times in (50 mM PBS, 500 mM NaCl, 20 mM imidazole, pH 7.4) and eluted in 3 \times 1 ml of elution buffer (50 mM PBS, 500 mM NaCl, 300 mM imidazole, pH 7.4). One hundred micrograms of the SUMO-binding Adhiron were biotinylated using NHS SS-biotin (Pierce) according to the manufacturer's instructions for use in enzyme-linked immunosorbent assay (ELISAs) and western blotting.

ELISA analysis with purified Adhiron

Unless otherwise indicated 5 ng of target protein in PBS was absorbed onto Immuno 96 Microwell™ Nunc MaxiSorp™ plate wells overnight at 4°C. Two hundred microlitre of 3 \times blocking buffer was added at 37°C for 4 h with no shaking. Biotinylated yeast SUMO-binding Adhiron (Ad-ySUMO) at 0.1 μ g/ml in Phosphate-buffered saline with Tween 20 (PBST) containing 2 \times blocking buffer were incubated in wells for 1 h with shaking. Wells were washed three times in PBST, and streptavidin conjugated to HRP (Invitrogen) diluted 1 : 1000 in 50 μ l PBST was added for 1 h. After washing Adhiron binding was visualised with 50 μ l TMB (Seramun) and the absorbance measured at 610 nm.

Western blot analysis

Target protein alone or mixed with HEK293 cell lysate (20 μ g) was mixed with loading buffer (60 mM Tris–Cl pH 6.8, 2% SDS, 10% glycerol, 5% β -mercaptoethanol, 0.01% bromophenol blue), boiled for 3 min, centrifuged for 1 min at 15 000g and then resolved in a 15% SDS–polyacrylamide gel. Proteins were transferred to PVDF membranes for 45 min at 4 W (Amersham Biosciences) and incubated for 1 h in blocking buffer (5% BSA in PBS 0.1% Tween) followed by incubation for 1 h with Ad-ySUMO (100 μ g/ml diluted 1 : 1000

PBST). Bound Ad-ySUMOs were detected using streptavidin-conjugated HRP and chemiluminescence (ECL Plus kit, Amersham).

Mass spectrometry analysis of Adhiron

Adhiron samples in PBS were buffer exchanged into 50 mM ammonium acetate using Zeba spin columns (7K MWCO; Thermo Scientific) and 20 ml samples of 20 mM protein were analysed on a Synapt HDMS (Waters UK Ltd) electrospray mass spectrometer.

Protein–protein interaction affinity measurement

The BLitz™ (ForteBio) dip and read streptavidin biosensors were used to estimate the affinity of ySUMO binding to immobilised biotinylated Ad-ySUMO binders, according to the manufacturer's instructions. At least four readings at different ySUMO concentrations (0.25–1 mM) were used for each Ad-ySUMO and a global fit was used to calculate binding affinities. The values obtained were comparable with affinities measured using a Biacore SPR3000 instrument.

DSC

Adhiron thermal stability was measured by differential scanning calorimetry (DSC) using a VP-DSC MicroCalorimeter (GE Healthcare). Each sample was dialysed extensively against PBS, pH 7.4 and diluted to a concentration of 1 mg/ml before heating from 10 to 100°C for Adhiron library clones or to 120°C for the Adhiron scaffold 92 and 81 amino acid proteins at an upscan rate of 90°C per hour. A buffer only scan was measured to calculate a baseline for integration. Data were fit to a one-state unfolding model and reversibility of thermal denaturation was determined by repeating the scan for the Adhiron scaffold sample without removing it from the cell.

ITC

All experiments were carried out using the iTC200 system (Microcal) at 25°C. Typically, 0.1 mM Adhiron protein was titrated with 0.01 mM of a target protein (yeast Sumo, human Sumo1, human Sumo2) by 2.5 min injection duration to allow return of the titration peak to the baseline. After fitting the integrated exothermic peaks, K_D values were determined using the Origin program (OriginLab).

CD studies

All circular dichroism (CD) measurements were performed on a Chirascan CD spectrometer (Applied Photophysics) at room temperature. The spectra were recorded over a wavelength range of 260–180 nm using a cuvette of 1 mm pathlength at a scan speed of 60 nm/min. The concentration of each sample was ca. 0.2 mg/ml in PBS buffer (pH 7.4). Data were further processed for noise reduction, baseline subtraction and signal averaging.

Structure determination

Crystallization trials were set up using the method of Walter et al. (2005). Crystals for the full-length Adhiron92 scaffold appeared after 38 days in Well H5 of a Morpheus screen (Molecular Dimensions) (0.02 M glycine, 0.02 M sodium L-glutamate, 0.02 M DL-alanine, 0.02 M DL-lysine hydrochloride, 0.02 M DL-serine, 0.1 M MOPS pH 7.50, 0.1 M HEPES sodium salt pH 7.50, 10.0% w/v polyethylene glycol 20 000, 20.0% w/v polyethylene glycol 550 MME). The shorter 81

amino acid Adhiron81 scaffold gave crystals after 52 days in Well D2 of the PACTpremier screen (Molecular Dimensions) (0.1 M Malic acid/MES/Tris Buffer System pH 5.0, 25.0% w/v Polyethylene Glycol 1500).

For the full-length Adhiron92 rod-like crystals $\sim 25 \mu\text{m}$ across were cryo-cooled directly into liquid nitrogen without the addition of cryoprotectants. Diffraction data were collected at beamline I24 at Diamond Light Source from multiple positions along a single crystal with the starting angle at each position offset by 30° with respect to the previous position. Data were collected to a resolution of 1.75 Å using an X-ray wavelength of 0.9686 Å with the beamsite set to be $20 \times 20 \mu\text{m}^2$ at the sample. For the shorter Adhiron-81 rod-like crystals $\sim 20 \mu\text{m}$ across grew in clumps. Diffraction data were collected from a single $20 \times 20 \times 20 \mu\text{m}^3$ crystal fragment.

All diffraction data were integrated using XDS (Kabsch, 2010) and scaled using AIMLESS (Evans, 2006). Phases were obtained via molecular replacement using PHASER (McCoy *et al.*, 2007). A subsection of a complex of an Adhiron bound to a soluble protein (manuscript in preparation) was used as a search model. Refinement was carried out using REFMAC (Murshudov *et al.*, 2011), PHENIX (Afonine *et al.*, 2012) and COOT (Emsley *et al.*, 2010). Full scaling and refinement statistics are presented in Tables I and II.

Results and discussion

Consensus phytocystatin

A consensus phytocystatin sequence was derived by identifying the most common amino acid at each position of an alignment of 57 phytocystatin sequences. The length of the initial consensus protein was set at 95 amino acids with the N-terminus positioned four residues before the conserved N-terminal glycine residue, and thus before the first β -strand ($\beta 1$). The C-terminus was set 15 residues after the conserved PW motif and thus after the last β -strand ($\beta 4$). These criteria were based on the structures of chicken egg white cystatin (Bode *et al.*, 1988) and human stefin B (Stubbs *et al.*, 1990) from X-ray structures and of OSA-I from the nuclear magnetic resonance structure (Nagata *et al.*, 2000).

Table I. Scaling and refinement statistics for Adhiron92

| | | | |
|--|---------------------------------|-------------|-------------|
| Average unit cell | 35.86, 35.86, 61.85; 90, 90, 90 | | |
| Space group | $P4_1$ | | |
| | Overall | Inner shell | Outer shell |
| Low resolution limit | 35.86 | 35.86 | 1.78 |
| High resolution limit | 1.75 | 9.09 | 1.75 |
| Rmerge (all I+ and I-) | 0.082 | 0.104 | 0.897 |
| Rmeas (all I+ and I-) | 0.085 | 0.108 | 0.960 |
| Rpim (all I+ and I-) | 0.023 | 0.029 | 0.326 |
| Rmerge in top intensity bin | 0.066 | – | – |
| Total number of obs | 101 109 | 737 | 3060 |
| Total number unique | 7889 | 62 | 398 |
| Mean ((I)/sd(I)) | 18.9 | 38.3 | 2.6 |
| Completeness | 99.3 | 99.5 | 91.6 |
| Multiplicity | 12.8 | 11.9 | 7.7 |
| Average mosaicity | 0.14 | | |
| Estimated B factor | 27.6 | | |
| Rwork/Rfree | 0.1829/0.2287 | | |
| RMS bonds | 0.007 Å | | |
| RMS angles | 1.072° | | |
| Residues in the favoured region of Ramachandran plot | 97.4% (75/77) | | |

Table II. Scaling and refinement statistics for Adhiron81

| | | | |
|--|---------------------------------|-------------|-------------|
| Average unit cell | 36.37, 36.37, 59.24; 90, 90, 90 | | |
| Space group | $P4_1$ | | |
| | Overall | Inner shell | Outer shell |
| Low resolution limit | 36.37 | 36.37 | 2.32 |
| High resolution limit | 2.25 | 9.00 | 2.25 |
| Rmerge (all I+ and I-) | 0.102 | 0.053 | 0.722 |
| Rmeas (all I+ and I-) | 0.119 | 0.062 | 0.839 |
| Rpim (all I+ and I-) | 0.060 | 0.031 | 0.423 |
| Rmerge in top intensity bin | 0.053 | – | – |
| Total number of obs | 13 790 | 209 | 1295 |
| Total number unique | 3709 | 64 | 339 |
| Mean((I)/sd(I)) | 8.2 | 17.5 | 1.8 |
| Completeness | 99.9 | 99.5 | 100.0 |
| Multiplicity | 3.7 | 3.3 | 3.8 |
| Average mosaicity | 0.21 | | |
| Estimated Bfactor | 33.7 | | |
| Rwork/Rfree | 0.1839/0.2477 | | |
| RMS bonds | 0.009 Å | | |
| RMS angles | 1.284° | | |
| Residues in the favoured region of Ramachandran plot | 93.5% (72/77) | | |

Adhiron scaffold design and phage display

The Adhiron scaffold was derived from the phytocystatin consensus protein by initial N-terminal truncation to a 92 amino acid sequence which we refer to as the full-length Adhiron scaffold, or Adhiron92. We subsequently generated further N-terminal truncated versions of which the shortest is an 81 amino acid sequence referred to as Adhiron81. The coding sequence for the full-length Adhiron, codon optimised to enhance expression in *E. coli* (Fig. 1A), was cloned into the phagemid vector pBSTG1 (Fig. 1B) to allow production of an Adhiron/truncated-pIII fusion protein in ER2738 suppressor cells for phage display.

Expression of the Adhiron-pIII fusion protein was confirmed by Western blot analysis with an anti-pIII antibody. The thermal stability of the Adhiron92 and Adhiron81 scaffolds was tested by DSC and both gave identical profiles with a melting temperature of 101°C (Fig. 2A). The secondary structure was examined by CD, and revealed a high ratio of β sheet to alpha helix and random coil (Fig. 2B). Electrospray mass spectrometry of Adhirons expressed from pET11 showed the predominant species to be lacking only the N-terminal Met, a common modification of cytoplasmically expressed proteins, with a minor component lacking MetAla.

Adhiron structure

We have determined the crystal structure of the full-length Adhiron92 scaffold by X-ray crystallography. The crystals belonged to space group of $P4_1$ and diffracted to a resolution of 1.75 Å (Table I; PDB ID code 4N6T). The overall structure comprises the characteristic cystatin family fold of a four-strand anti-parallel β -sheet core with a central helix (Fig. 3). Amino acids 1–10 and 90–92 are not visible in the electron density maps presumably as they are disordered. The shorter Adhiron81 also crystallised in space group $P4_1$ and the structure determined to 2.25 Å resolution (Table II; PDB ID code 4N6U) was essentially identical to that of Adhiron92. The Adhiron structure is compact with limited unstructured loops and this is consistent with the very high melting temperature of this consensus protein.




Fig. 2. Characterisation of the Adhiron scaffold and library. (A) DSC to determine the melting temperature of the Adhiron scaffold (T_m 101°C). (B) Ninety-six random clones were isolated and sequenced both as the phagemid transformed and Adhiron phage library infected *E. coli* ER2738 cells. The percentage of each amino acid within the variable regions is shown. An ideal library would contain $5.26 \pm 2.3\%$ of each amino acid; cysteine was not included in the library. (C) CD analysis of the Adhiron scaffold and of three Adhiron proteins containing inserts from the library. All show high β structure content.

Library design

The introduction of peptide encoding sequences, suitable for molecular recognition, was guided by the predicted loop positions within the known structure of the rice phycocystatin




Fig. 3. X-ray crystal structure of Adhiron92 scaffold (PDB ID no. 4N6T) at 1.75 Å resolution. The single alpha helix and the four anti-parallel β strands are shown in white with the insertion sites for library production shown in black. Residues 1–10 and 90–92 are not visible in the structure and are presumably disordered. The structure of Adhiron81 at 2.25 Å resolution (PDB ID no. 4N6U) is essentially identical.

OC-1 (PDB code 1EQK). VR 1 was positioned between the first and second β strands with VR 2 between the third and fourth β strands (Fig. 3). Sequences encoding nine random amino acids (excluding cysteine) were introduced at Loops 1 and 2 by replacing four and three amino acid codons, respectively, by using codon-selected semi-trinucleotide cassette synthesis. The phage-display library was estimated to comprise $\sim 1.3 \times 10^{10}$ independent clones obtained with just 12.6 μg of ligated DNA attributable to high ligation and electroporation efficiencies. To check the amino acid composition, 96 random clones were selected as colonies from the original transformation and revealed no bias in amino acid composition and ca. 94% full-length clones. Following phage recovery and library re-infection of ER2738 cells, a further 96 clones were randomly sequenced. The amino acid residue frequency (Fig. 2B) encoded at the phage level met the expected Poisson statistics of $5.26 \pm 2.3\%$ for trimer synthesized oligos using a 19-aa mixture (Krumpe et al., 2007). Clones (86.5%) were full length with only 3.1% clones comprising the Adhiron scaffold with no inserts, and 10.4% clones showing frame shifts. Interestingly, all frame-shift mutants analysed occurred at the transition base between standard nucleotide and trimer coupling, suggesting that this step of DNA synthesis is of crucial importance for semi-trimer oligo synthesis. Fully trimer synthesised oligos might therefore be expected to further improve library quality. However, of the insertions and deletions, between 3 and 8% were unlikely to impact on Adhiron

function as the affected variants remain in frame. The high proportion of full-length coding regions at the level of phage-mid following phage packaging demonstrates the high quality of the library generated.

Three random Adhiron clones containing inserts were used for protein purification and CD was performed (Fig. 2C). All three showed a high proportion of β structure, as found in parental phycocystatins (Irene D *et al.*, 2012), with one protein displaying a higher content of β structure likely indicating extension of the β strands from the scaffold into the insert regions. This demonstrates that the scaffold can tolerate insertion of peptides in these loop regions and these do not disrupt the secondary structure of the scaffold.

Library screening

For library evaluation, the ySUMO protein was used as a model target. Over 1000-fold amplification in colony recovery was observed compared with control samples by panning round three. Twenty-four Adhiron clones were isolated and their ability to bind to ySUMO was confirmed by phage ELISA (Fig. 4A) with little or no binding to the control wells. The clones were sequenced and 22 distinct Adhiron termed Adh-ySUMO 1–22 were identified with the amino acid sequences of the VRs shown in Table III.

Ad-ySUMO 4 and 5 are identical and 16 and 22 are also identical. Interestingly Ad-ySUMO 15 and 23, as well as 21

and 22, contain the same amino acid sequence in VR 1 but different sequences in VR 2. Analysis of the sequences allowed identification of a commonly occurring SUMO Interacting Motif (SIM) (Kerscher, 2007; Li *et al.*, 2010; Sun and Hunter, 2012) sequence IDLT in Positions 1–4 of VR 1 in 12 of the Ad-ySUMOs, indicating that this is likely to be an important motif in binding to at least one epitope on ySUMO. This SIM motif was not found in VR 2 in any of the clones analysed. Interestingly, the IDLT motif is similar to the human SUMO 1 binding site of the MEF2 E3 ligase PIASx (VDVIDLT) (Song *et al.*, 2004; Song *et al.*, 2005). Either a P or G was identified at Position 1 of VR 2 in nine different Adhiron while a P or G occurs in a position between Residues 2–5 in another 6 Adhiron potentially indicating that some structural feature may be important in binding. For example, clones ySUMO21, 22, 23 and 24 which have the IDLT motif in VR 1 have the motif $PX_{1-3}(N/Q)(W/F/Y)$ or $G(L,I)$, which is not found in VR 1. We also identified a common pattern $(W/F/Y)(E/D)_{2-4}(W/F/Y)$ represented in both VRs. This molecular pattern matches the criteria for SIMs; a high percentage of hydrophobic amino acids juxtaposed with acidic residues (Song *et al.*, 2005), suggesting that both VRs may act independently, but contribute to the overall binding.

Four Ad-ySUMOs were selected for further characterisation, Clones 15 and 22 as the VR 1 sequence occurred multiple times, Clone 10 as it contained the IDLT motif and Clone 19 as it contained a distinct motif in VR 1.




Fig. 4. Isolation and purification of yeast SUMO-binding Adhiron. (A) Phage ELISA of Adhiron from 24 clones incubated in wells containing ySUMO (black) or control (grey) showing the TMB product absorbance at 560 nm after 3 min. incubation. (B) Ad-ySUMOs were expressed in BL21 (DE3) cells and cell lysates were heated to 20, 50, 60, 70, 80, 90, 100 and 100°C for 20 min then 5 μ l of cleared lysates was separated by 15% SDS-PAGE and Coomassie stained. (C) Ad-ySUMO purification by Ni-NTA beads and analysis of the purified Ad-ySUMOs by 15% SDS-PAGE with Coomassie staining. (D) DSC of Ad-ySUMO clones 10, 15, 20 and 22 together with the Adhiron scaffold.

Table III. Adhiron insert sequences for 24 yeast SUMO-binding Adhiron

| Ad-ySUMO | LOOP1 | LOOP2 |
|----------|------------|------------|
| 1 | WDLTGNVDT | WDDWGERFW |
| 2 | IDLTFNSFAS | DINQYWHSM |
| 3 | INLMMVSPM | GIQQNPSHA |
| 4 | IDLTHSLNY | GLTNEIQKM |
| 5 | IDLTHSLNY | GLTNEIQKM |
| 6 | IDLTEWQDR | PEPIHSHHS |
| 7 | WVDMDDYYWR | MDEIWAIEYA |
| 8 | IDLTQTEIV | EPGIPIVH |
| 9 | IDLTDVWID | GLMTQTNSM |
| 10 | IIIHENDAD | GIMDGLNKY |
| 11 | WILNNTQFI | VLEGPDRWTV |
| 12 | WYERSENWD | RDYGFSLVP |
| 13 | WDLTTPINI | YEDYQTPMY |
| 14 | WFDDEYDWI | DYAATDLYW |
| 15 | IDLTPHDS | YEEDEYWRM |
| 16 | IDLTSQFDM | PIDSNFTGT |
| 17 | WYLLDVMD | HDHRYKQAE |
| 18 | WIDRGQYWD | IHNGYTMD |
| 19 | WSEADNDWH | LDLETWQHF |
| 20 | IDLTGQWLF | PLWQYDAQY |
| 21 | IDLTSQFDM | PSHHNYQTM |
| 22 | IDLTSQFDM | PIDSNFTGT |
| 23 | IDLTPHDS | PHDELNWNM |
| 24 | WEDFQTHWE | DVGQLLSGI |

Characterisation of the ySUMO Adhiron (Ad-ySUMO)

Due to the high thermal stability of the Adhiron scaffold (Fig. 2A), we predicted that purification may be aided by introducing a heating step to denature and precipitate the majority of *E. coli* proteins without affecting Adhiron integrity. We therefore heated lysates for 20 min at 20, 50, 60, 70, 80, 90 and 100°C, centrifuged to pellet the denatured protein and analysed the supernatants by SDS-PAGE (Fig. 4B). The heating step dramatically decreased the quantity of bacterial protein but did not significantly reduce Adhiron levels. A temperature of 50°C was suitable to remove the majority of bacterial proteins and so was adopted. Figure 4C demonstrates that the purified Ad-ySUMOs show high purity using a batch metal affinity purification method. The estimated level of Adhiron expressed was ~100 mg/l. DSC confirmed the selected Adhiron maintained heat stability, showing T_m 's of 95.2, 87.7, 87 and 86.7°C for Ad-ySUMO 10, 15, 19 and 22, respectively (Fig. 4D). This demonstrates the ability of the scaffold to effectively constrain the VRs while maintaining high thermal stability of different Adhiron variants. This is consistent with previous observations reported for DARPins that the introduction of diversity results in some loss of stability (Binz *et al.*, 2003; Kohl *et al.*, 2003; Wetzel *et al.*, 2008). However, unlike DARPins we are introducing 18 variable




Fig. 5. Characterisation of yeast SUMO-binding Adhiron, Ad-ySUMO 10, 15, 20 and 22. (A) Biotinylated Ad-ySUMOs were used to detect ySUMO (black). Human SUMO 1 (light grey) and human SUMO 2 (dark grey) by ELISA with TMB product detected at 560 nm. (B) Western blots using biotinylated Ad-ySUMO clones against yeast SUMO alone (upper panel) and mixed with 20 µg of HEK293 cell lysate (lower panel). (C) Western blot analysis using biotinylated Ad-ySUMO clones against yeast and human SUMOs 1 and 2. (D) Isothermal calorimetry of Ad-ySUMOs binding to yeast SUMO with the isotherms and the data fits.

amino acid residues by replacing two short loops of a non-repeat protein scaffold and so the retention of such high thermostability is notable. Fibronectins and the leucine-rich repeat-based Repobodies have reported melting temperatures of around 90°C (Jacobs *et al.*, 2012) and 85°C (Lee *et al.*, 2012), respectively.

To evaluate the use of the Adhirons as research reagents, the Ad-ySUMOs were biotinylated and used in ELISA (Fig. 5A) and western blot analysis (Fig. 5B and C). The Ad-ySUMOs show selectivity by binding to yeast SUMO but not to human SUMO 1 or 2 ($n = 3$). To determine the specificity of the reagents, yeast SUMO was mixed with HEK293 cell lysates. Interestingly, Ad-ySUMO 10 and 15 show specific binding to yeast SUMO with no binding to other proteins whereas Ad-ySUMO 19 and 22 bind to other proteins in the lysates ($n = 3$), indicating that the inserted sequences are more promiscuous, emphasising the importance of strict negative screens during panning. The affinities of the Adhirons for ySUMO were measured by isothermal titration calorimetry (ITC). Ad-ySUMO 10, 15, 20 and 22 bound with K_D values of 29.6 ± 0.8 , 33.3 ± 1.8 , 45.8 ± 8.8 and 47 ± 15.6 nM, respectively (Fig. 5D). Similar affinities were observed using the Blitz™ analysis (ForteBio) when the Adhirons were immobilised on a biosensor surface which validates the use of the Blitz™ for rapid estimation of binding affinity ranges. These K_D values are in line with those observed for antibodies. By contrast, the K_D values for human SUMO 1 and 2 were $>10^3$ -fold higher at 15 and 50 μ M, respectively (data not shown). The binding affinities of human SUMO 1 and 2 to a peptide bearing the conserved IDLT SIM motif have been reported to be in the range of 5–6 μ M (Song *et al.*, 2005; Li *et al.*, 2010), which is in agreement with our data. The higher affinity for yeast SUMO than the human SUMOs indicates that sequences other than the IDLT in VR 1 and/or 2 play a discriminating role in ySUMO binding. The affinities obtained for the yeast SUMO binders are in the same range as those against other targets reported for DARPins (Schweizer *et al.*, 2007; Steiner *et al.*, 2008) and monobodies (Gilbreth *et al.*, 2011; Grebien *et al.*, 2011), suggesting that the Adhiron scaffold is competitive with other non-antibody binding proteins.

Further example screens

To further evaluate the functionality of the Adhiron library, we identified binders to other targets, including the growth factor (FGF1), receptor (CD31), SH2 domain Grb2 and a peptide sequence. All screens were performed over three panning rounds. Phage ELISA was used to examine the ability of recovered Adhirons to bind to the corresponding target (Fig. 6). While the majority of the FGF1, CD31 and Grb2 Adhirons showed specific binding, this was not the case for the peptide screen. In this case, specificity was enhanced by increasing the number of panning rounds. This is not unexpected due to the small size and limited likelihood of appropriate epitope presentation by the peptide compared with larger proteins likely to allow better presentation of single or multiple epitopes. To further confirm that expressed Adhirons bind to their targets, we have used the Blitz™ to analyse three distinct recombinant Adhirons for both CD31 and the peptide target. The Adhirons were expressed and purified as soluble proteins. The K_D values for CD31 Adhirons ranged from 8.5×10^{-8} to 6.8×10^{-9} M, while those for the peptide ranged from 3.3×10^{-8} to 3.5×10^{-8} . These data further




Fig. 6. Phage ELISA results for Adhirons identified in screens against (A) growth factor protein FGF1, (B) cell surface receptor CD31 and (C) a peptide. Graphs show absorbance readings of each well after the addition of TMB. Wells containing the target molecule are shown in black and control wells are shown in grey.

demonstrate that the phage ELISA identifies high affinity Adhirons.

Analysis of our screen against Grb2 offered the opportunity to directly compare the efficacy of our Adhiron library against well-established ScFv and Fab libraries. A recent study reported high throughput screens of 20 SH2 domains using both hybridoma and phage-display libraries of ScFv's (Colwill *et al.*, 2011). This allows comparison of the results for Grb2 from this study with our screen against Grb2. The hit rates for two ScFv and a Fab library were 4, 43 and 33% (410 clones screened in total) with 5, 2 and 6 unique clones identified from each screen, respectively. In our screen, the hit rate was 92% with over 30 unique binders, although not all were sequenced. Our Adhiron purification success rate was $>95\%$

with typical yields of 50–100 mg/l compared with the reported purification success rate of 80% with yields of 0.6–10 mg/l. This is a limited comparative study but demonstrates the complexity of the Adhiron library and the potential for generating specific protein binding reagents.

Conclusions

We have developed a new artificial binding protein scaffold termed Adhiron based on a designed consensus phycocystatin protein. The properties of this scaffold also match the criteria proposed for artificial therapeutic proteins (Carter, 2011) although it remains to be determined whether Adhiron will be suitable for such applications. The design of the scaffold and library provides a system based on a highly stable scaffold with extended flexible binding regions that are expected to adapt to form appropriate molecular contacts with a wide range of targets allowing interactions with protein pockets, protein surfaces, peptides and small molecules. The system achieves high-level purification of soluble Adhiron (typically 10–100 mg/l) from *E. coli*, by including a heat enrichment step enabling ease of engineering and manufacture. The scaffold displays high thermostability with a melting temperature of 101 °C determined by DSC (Fig. 2A).

We have solved the X-ray crystal structure of the Adhiron scaffold reported here, as well as selected Adhiron in complex with target proteins which will be reported elsewhere. The ability to gain structural information is important for improving our understanding of the molecular interactions of Adhiron with their targets that lead to functional consequences, and to provide a basis for drug design. We are currently exploring the extent to which the Adhiron scaffold may offer a platform for selection of reagents for applications including research tools, diagnostic, imaging, therapeutic agents and for drug discovery.

Supplementary material

Supplementary material is available at *PEDS* online.

Acknowledgements

The authors thank Iain Manfield for assistance with ITC and DSC experiments, G. Nasir Khan for assistance with CD experiments and James Ault for performing mass spectrometry. D.J.H. was in receipt of a Biotechnology and Biological Sciences Research Council studentship.

Conflict of interest

Work reported here is included in a patent application filed by the University of Leeds.

Funding

This work was supported by the Biotechnology and Biological Sciences Research Council [24/G15882] for the development of the consensus cystatin. The scaffold development work was funded by University of Leeds Transformation Fund support for the Biomedical Health Research Centre BioScreening Technology Group. Part of this work concerning characterisation of Adhiron was supported through WELMEC, a Centre of Excellence in Medical Engineering funded by the Wellcome Trust and EPSRC, under grant number WT 088908/Z/09/Z.

The OPPF-UK is supported by the MRC and BBSRC. Funding to pay the Open Access publication charges for this article was provided by The Wellcome Trust.

References

- Afonine, P.V., Grosse-Kunstleve, R.W., Echols, N., et al. (2012) *Acta Crystallogr. D*, **68**, 352–367.
- Binz, H.K., Stumpp, M.T., Forrer, P., Amstutz, P. and Pluckthun, A. (2003) *J. Mol. Biol.*, **332**, 489–503.
- Bode, W., Engh, R., Musil, D., Thiele, U., Huber, R., Karshikov, A., Brzin, J., Kos, J. and Turk, V. (1988) *EMBO J.*, **7**, 2593–2599.
- Carter, P.J. (2011) *Exp. Cell Res.*, **317**, 1261–1269.
- Colwill, K., Graslund, S. and Renewable Prot Binder Working, G. (2011) *Nat. Methods*, **8**, 551–558.
- Corpet, F. (1988) *Nucleic Acids Res.*, **16**, 10881–10890.
- Emsley, P., Lohkamp, B., Scott, W.G. and Cowtan, K. (2010) *Acta Crystallogr. D*, **66**, 486–501.
- Evans, P.R. (2006) *Acta Crystallogr. D*, **62**, 72–82.
- Forrer, P., Binz, H.K., Stumpp, M.T. and Pluckthun, A. (2004) *ChemBiochem*, **5**, 183–189.
- Gebauer, M. and Skerra, A. (2009) *Curr. Opin. Chem. Biol.*, **13**, 245–255.
- Gilbreth, R.N., Truong, K., Madu, I., Koide, A., Wojcik, J.B., Li, N.-S., Piccirilli, J.A., Chen, Y. and Koide, S. (2011) *Proc. Natl. Acad. Sci. USA*, **108**, 7751–7756.
- Grebien, F., Hantschel, O., Wojcik, J., et al. (2011) *Cell*, **147**, 306–319.
- Hoogenboom, H.R., Griffiths, A.D., Johnson, K.S., Chiswell, D.J., Hudson, P. and Winter, G. (1991) *Nucleic Acids Res.*, **19**, 4133–4137.
- Horton, R., Cai, Z., Ho, S. and Pease, L. (1990) *Biotechniques*, **8**, 528–535.
- Irene, D., Chung, T.-Y., Chen, B.-J., Liu, T.-H., Li, F.-Y., Tzen, J.T.C., Wang, C.-I. and Chyan, C.L. (2012) *PLoS ONE*, **7**, e47865.
- Jacobs, S.A., Diem, M.D., Luo, J., Teplyakov, A., Obmolova, G., Malia, T., Gilliland, G.L. and O'Neil, K.T. (2012) *PEDS*, **25**, 107–117.
- Kabsch, W. (2010) *Acta Crystallogr. D*, **66**, 125–132.
- Kerscher, O. (2007) *EMBO Rep.*, **8**, 550–555.
- Knappik, A., Ge, L.M., Honegger, A., et al. (2000) *J. Mol. Biol.*, **296**, 57–86.
- Kohl, A., Binz, H.K., Forrer, P., Stumpp, M.T., Pluckthun, A. and Grutter, M.G. (2003) *Proc. Natl. Acad. Sci. USA*, **100**, 1700–1705.
- Koide, A., Bailey, C.W., Huang, X.L. and Koide, S. (1998) *J. Mol. Biol.*, **284**, 1141–1151.
- Komor, R.S., Romero, P.A., Xie, C.B. and Arnold, F.H. (2012) *PEDS*, **25**, 827–833.
- Kondo, H., Abe, K., Emori, Y. and Arai, S. (1991) *FEBS Lett.*, **278**, 87–90.
- Krumpe, L.R., Schumacher, K.M., McMahon, J.B., Makowski, L. and Mori, T. (2007) *BMC Biotechnol.*, **7**, 65.
- Lee, S.-C., Park, K., Han, J., et al. (2012) *Proc. Natl. Acad. Sci. USA*, **109**, 3299–3304.
- Lehmann, M., Kostrewa, D., Wyss, M., Brugger, R., D'Arcy, A., Pasamontes, L. and van Loon, A. (2000) *Protein Eng.*, **13**, 49–57.
- Li, Y.J., Stark, J.M., Chen, D.J., Ann, D.K. and Chen, Y. (2010) *Oncogene*, **29**, 3509–3518.
- Main, E.R.G., Xiong, Y., Cocco, M.J., D'Andrea, L. and Regan, L. (2003) *Structure*, **11**, 497–508.
- McCoy, A.J., Grosse-Kunstleve, R.W., Adams, P.D., Winn, M.D., Storoni, L.C. and Read, R.J. (2007) *J. Appl. Crystallogr.*, **40**, 658–674.
- Mosavi, L.K., Minor, D.L. and Peng, Z.Y. (2002) *Proc. Natl. Acad. Sci. USA*, **99**, 16029–16034.
- Murshudov, G.N., Skubak, P., Lebedev, A.A., Pannu, N.S., Steiner, R.A., Nicholls, R.A., Winn, M.D., Long, F. and Vagin, A.A. (2011) *Acta Crystallogr. D*, **67**, 355–367.
- Nagata, K., Kudo, N., Abe, K., Arai, S. and Tanokura, M. (2000) *Biochemistry*, **39**, 14753–14760.
- Nixon, A.E. and Wood, C.R. (2006) *Curr. Opin. Drug Discov. Develop.*, **9**, 261–268.
- Nord, K., Nilsson, J., Nilsson, B., Uhlen, M. and Nygren, P.A. (1995) *Protein Eng.*, **8**, 601–608.
- Parizek, P., Kummer, L., Rube, P., Prinz, A., Herberg, F.W. and Pluckthun, A. (2012) *ACS Chem. Biol.*, **7**, 1356–1366.
- Reichert, J.M. (2010) *MABS*, **2**, 84–100.
- Schellenberger, V., Wang, C.-w., Geething, N.C., et al. (2009) *Nat Biotechnol.*, **27**, 1186–1190.
- Schlehuber, S. and Skerra, A. (2005) *Expert Opin. Biol. Ther.*, **5**, 1453–1462.
- Schweizer, A., Roschitzki-Voser, H., Amstutz, P., et al. (2007) *Structure*, **15**, 625–636.
- Skerra, A. (2007) *Curr. Opin. Biotechnol.*, **18**, 295–304.

- Song,J., Durrin,L.K., Wilkinson,T.A., Krontiris,T.G. and Chen,Y.A. (2004) *Proc. Natl Acad. Sci. USA*, **101**, 14373–14378.
- Song,J., Zhang,Z.M., Hu,W.D. and Chen,Y. (2005) *J. Biol. Chem.*, **280**, 40122–40129.
- Steiner,D., Forrer,P. and Plueckthun,A. (2008) *J. Mol. Biol.*, **382**, 1211–1227.
- Steipe,B., Schiller,B., Pluckthun,A. and Steinbacher,S. (1994) *J. Mol. Biol.*, **240**, 188–192.
- Stubbs,M.T., Laber,B., Bode,W., Huber,R., Jerala,R., Lenarcic,B. and Turk,V. (1990) *EMBO J.*, **9**, 1939–1947.
- Sun,H. and Hunter,T. (2012) *J. Biol. Chem.*, **287**, 42071–42083.
- Theurillat,J.-P., Dreier,B., Nagy-Davidescu,G., Seifert,B., Behnke,S., Zuerrer-Haerdi,U., Ingold,F., Plueckthun,A. and Moch,H. (2010) *Mod. Pathol.*, **23**, 1289–1297.
- Walter,T.S., Diprose,J.M., Mayo,C.J., *et al.* (2005) *Acta Crystallogr. D*, **61**, 651–657.
- Wetzel,S.K., Settanni,G., Kenig,M., Binz,H.K. and Pluckthun,A. (2008) *J. Mol. Biol.*, **376**, 241–257.
- Wojcik,J., Hantschel,O., Grebien,F., *et al.* (2010) *Nat. Struct. Mol. Biol.*, **17**, 519–U173.
- Wurch,T., Pierre,A. and Depil,S. (2012) *Trends Biotechnol.*, **30**, 575–582.